Provectus Biopharmaceuticals Net Income
| PVCT Stock | USD 0.04 0 6.82% |
As of the 11th of February 2026, Provectus Biopharmaceutica holds the Coefficient Of Variation of (1,157), variance of 45.62, and Risk Adjusted Performance of (0.06). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Provectus Biopharmaceutica, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to break down thirteen technical drivers for Provectus Biopharmaceutica, which can be compared to its competitors.
Analyzing historical trends in various income statement and balance sheet accounts from Provectus Biopharmaceutica's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Provectus Biopharmaceutica's valuation are summarized below:Provectus Biopharmaceuticals does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Provectus |
Provectus Biopharmaceutica 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Provectus Biopharmaceutica's otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Provectus Biopharmaceutica.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Provectus Biopharmaceutica on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Provectus Biopharmaceuticals or generate 0.0% return on investment in Provectus Biopharmaceutica over 90 days. Provectus Biopharmaceutica is related to or competes with Defence Therapeutics, Sernova Corp, Cynata Therapeutics, Starpharma Holdings, Celyad Oncology, and Microbix Biosystems. Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicine... More
Provectus Biopharmaceutica Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Provectus Biopharmaceutica's otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Provectus Biopharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.10) | |||
| Maximum Drawdown | 32.52 | |||
| Value At Risk | (9.52) | |||
| Potential Upside | 13.11 |
Provectus Biopharmaceutica Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Provectus Biopharmaceutica's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Provectus Biopharmaceutica's standard deviation. In reality, there are many statistical measures that can use Provectus Biopharmaceutica historical prices to predict the future Provectus Biopharmaceutica's volatility.| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.56) | |||
| Total Risk Alpha | (1.29) | |||
| Treynor Ratio | 1.39 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Provectus Biopharmaceutica's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Provectus Biopharmaceutica February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | 1.4 | |||
| Mean Deviation | 4.81 | |||
| Coefficient Of Variation | (1,157) | |||
| Standard Deviation | 6.75 | |||
| Variance | 45.62 | |||
| Information Ratio | (0.10) | |||
| Jensen Alpha | (0.56) | |||
| Total Risk Alpha | (1.29) | |||
| Treynor Ratio | 1.39 | |||
| Maximum Drawdown | 32.52 | |||
| Value At Risk | (9.52) | |||
| Potential Upside | 13.11 | |||
| Skewness | 0.4302 | |||
| Kurtosis | 1.23 |
Provectus Biopharmaceutica Backtested Returns
Provectus Biopharmaceutica maintains Sharpe Ratio (i.e., Efficiency) of -0.0784, which implies the firm had a -0.0784 % return per unit of risk over the last 3 months. Provectus Biopharmaceutica exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Provectus Biopharmaceutica's Coefficient Of Variation of (1,157), variance of 45.62, and Risk Adjusted Performance of (0.06) to confirm the risk estimate we provide. The company holds a Beta of -0.43, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Provectus Biopharmaceutica are expected to decrease at a much lower rate. During the bear market, Provectus Biopharmaceutica is likely to outperform the market. At this point, Provectus Biopharmaceutica has a negative expected return of -0.54%. Please make sure to check Provectus Biopharmaceutica's total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Provectus Biopharmaceutica performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.29 |
Poor predictability
Provectus Biopharmaceuticals has poor predictability. Overlapping area represents the amount of predictability between Provectus Biopharmaceutica time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Provectus Biopharmaceutica price movement. The serial correlation of 0.29 indicates that nearly 29.0% of current Provectus Biopharmaceutica price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.29 | |
| Spearman Rank Test | 0.23 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Provectus Biopharmaceuticals reported net income of (5.54 Million). This is 101.62% lower than that of the Pharmaceuticals sector and 107.91% lower than that of the Health Care industry. The net income for all United States stocks is 100.97% higher than that of the company.
Provectus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Provectus Biopharmaceutica's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Provectus Biopharmaceutica could also be used in its relative valuation, which is a method of valuing Provectus Biopharmaceutica by comparing valuation metrics of similar companies.Provectus Biopharmaceutica is currently under evaluation in net income category among its peers.
Provectus Fundamentals
| Return On Asset | -1.85 | |||
| Operating Margin | (4.77) % | |||
| Current Valuation | 46.73 M | |||
| Shares Outstanding | 419.55 M | |||
| Shares Owned By Insiders | 3.69 % | |||
| Shares Owned By Institutions | 0.04 % | |||
| Number Of Shares Shorted | 1.82 M | |||
| Price To Earning | (0.48) X | |||
| Price To Book | 5.44 X | |||
| Price To Sales | 55.94 X | |||
| EBITDA | (4.56 M) | |||
| Net Income | (5.54 M) | |||
| Cash And Equivalents | 84.27 K | |||
| Total Debt | 2.29 M | |||
| Debt To Equity | 0.25 % | |||
| Current Ratio | 0.27 X | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (1.01 M) | |||
| Short Ratio | 0.47 X | |||
| Earnings Per Share | (0.01) X | |||
| Target Price | 3.5 | |||
| Beta | 0.5 | |||
| Market Capitalization | 44.47 M | |||
| Total Asset | 3.51 M | |||
| Retained Earnings | (180.8 M) | |||
| Working Capital | 10.6 M | |||
| Current Asset | 14.72 M | |||
| Current Liabilities | 4.12 M | |||
| Z Score | -59.7 | |||
| Net Asset | 3.51 M |
About Provectus Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Provectus Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Provectus Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Provectus Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Provectus OTC Stock Analysis
When running Provectus Biopharmaceutica's price analysis, check to measure Provectus Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Provectus Biopharmaceutica is operating at the current time. Most of Provectus Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Provectus Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Provectus Biopharmaceutica's price. Additionally, you may evaluate how the addition of Provectus Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.